Platinum Sponsor

Gold Sponsors

Silver Sponsors

Associate Sponsors

Home Live TV Live Blog Highlights Cheaper Dearer Rate News Opinion Videos More
You are here:HomeBudgetPharma

Pharma

  • Ranbaxy Loses Approvals, Exclusivity of 2 Drugs in US

    Ranbaxy Loses Approvals, Exclusivity of 2 Drugs in US

    Ranbaxy Laboratories' tentative approvals for its generic versions of digestive disorder drug Nexium and antiviral Valcyte along with 180-days marketing exclusivity stands canceled following a US court decision.

  • Sun Pharma to Buy GSK's Opiates Business in Australia

    Sun Pharma to Buy GSK's Opiates Business in Australia

    Sun Pharmaceutical Industries, India's largest drugmaker by sales, said on Tuesday it has agreed to buy GlaxoSmithKline's opiates business in Australia.

  • Price Performance of Pharma Stocks Other Stories
  • Natco Pharma Ties Up With Gilead on Hepatitis C Drugs

    Natco Pharma Ties Up With Gilead on Hepatitis C Drugs

    Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.

  • Glenmark Gets FDA Nod to Sell Blood Pressure Drug

    Glenmark Gets FDA Nod to Sell Blood Pressure Drug

    Glenmark Pharmaceuticals on Thursday announced receipt of approval from the US Food and Drug Administration (FDA) to sell its generic version of AbbVie Inc's blood pressure drug Tarka in the American market.

  • US Regulator Raises Concerns on Waluj Plant: Wockhardt

    US Regulator Raises Concerns on Waluj Plant: Wockhardt

    Shares in Wockhardt Ltd fell as much as 5.3 per cent on Thursday after the drug maker said the US Food and Drug Administration (FDA) had raised fresh concerns about a plant already banned from exporting to the United States over quality issues.

  • Lupin Ties Up With Bangalore-Based Acceliant

    Lupin Ties Up With Bangalore-Based Acceliant

    Pharma major Lupin has tied up with Acceliant to use the Bangalore-based firm's platform in its drug research programmes.

  • Dr Reddy's Drug Pricing Mechanism Under Probe in US

    Dr Reddy's Drug Pricing Mechanism Under Probe in US

    The development comes after two members of the United States Congress wrote to the company requesting information and expressing "concern" over the "escalating prices" of two products -- divalproex sodium ER and pravastatin sodium -- marketed by it in the United States.

  • Glenmark Gets US Regulatory Nod for Contraceptive Drug

    Glenmark Gets US Regulatory Nod for Contraceptive Drug

    Glenmark Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for generic Ashlyna contraceptive tablets and launched them in the American market.

  • Jubilant Life Gets USFDA Nod for Hypertension, Allergies Drugs

    Jubilant Life Gets USFDA Nod for Hypertension, Allergies Drugs

    The company has received final approval from US Food and Drug Administration for its abbreviated new drug application for Irbesartan tablets in the strengths of 75 mg, 150 mg, 300 mg and for chewable Cetirizine Hydrochloride tablets in the strengths of 5 mg and 10 mg, Jubilant Life Sciences said.

  • Sun Pharma Recalls 3,263 Bottles of Epilepsy Drug in US

    Sun Pharma Recalls 3,263 Bottles of Epilepsy Drug in US

    The 750 mg tablets in 60-count bottles, were manufactured by Sun Pharmaceutical Industries at Halol.

  • Wockhardt Seeks Shareholders' Nod for Financial Flexibility

    Wockhardt Seeks Shareholders' Nod for Financial Flexibility

    The company is also seeking shareholders' approval via postal ballot to re-appoint Habil Khorakiwala as chairman of the company for a tenure of five years with effect from March 1, 2015 to February 29, 2020

  • Lupin Launches Asthma Drug Delivery Device in US

    Lupin Launches Asthma Drug Delivery Device in US

    Lupin Pharmaceuticals Inc (LPI), a subsidiary of the company, has launched the all new InspiraChamber anti-static valved holding chamber (VHC) under a strategic licensing agreement with InspiRX Inc, the Mumbai-based firm said in a statement.

  • Lupin Ties Up with Poland-Based Firm for Asthama Drug

    Lupin Ties Up with Poland-Based Firm for Asthama Drug

    As per the agreement inked between the two companies, Lupin will be responsible for commercialisation of the product.

  • Natco Pharma's US Partner Mylan Files Application With USFDA

    Natco Pharma's US Partner Mylan Files Application With USFDA

    The company's marketing partner Mylan Inc has filed an abbreviated new drug application (ANDA) for Sorafenib tablets in the strength of 200mg with the US Food and Drug Administration (USFDA), Natco Pharma said in a filing to the BSE on Wednesday.

  • Natco Pharma Files for New Drug Applications with USFDA

    Natco Pharma Files for New Drug Applications with USFDA

    The company has filed Abbreviated New Drug Applications (ANDAs) for Fingolimod, 0.5 mg capsules and Cabazitaxel, 60mg/ 1.5ml injection, with the US Food and Drug Administration, through its respective marketing partners, Natco Pharma said in a filing to the BSE.

  • Cipla Forms Joint Venture to Enhance Position in African Market

    Cipla Forms Joint Venture to Enhance Position in African Market

    The initial focus of the JV shall be respiratory and neurology products and it shall also invest in setting up a manufacturing facility in Morocco, it added.

  • USFDA to Increase its India Headcount

    USFDA to Increase its India Headcount

    Solomon Yimam, Assistant Country Director, US FDA India Office while denying that the inspections are targeted, said the frequency of audits of Indian facilities would depend on the number of product applications filed from that facility.

  • Mylan to Acquire Famy Care's Women's Health Business for $800 Million

    Mylan to Acquire Famy Care's Women's Health Business for $800 Million

    Mylan Inc will acquire certain businesses of Mumbai-based Famy Care Ltd, a specialty women's health care company, for a total consideration of $800 million (over Rs 4,940 crore).

  • RBI Notifies New FDI Policy for Medical Devices Segment

    RBI Notifies New FDI Policy for Medical Devices Segment

    The Reserve Bank of India on Monday notified changes in the foreign direct investment (FDI) policy allowing 100 per cent FDI in medical devices segment.

  • Lupin Gets USFDA Approval for Diarrhoea Drug

    Lupin Gets USFDA Approval for Diarrhoea Drug

    The company has received final approval for its Vancomycin Hydrochloride Capsules in strengths of 125 mg and 250 mg from the US Food and Drugs Administration (FDA) to market a generic version of ANI Pharmaceuticals, Inc's Vancocin, Lupin Ltd said in a statement.

Advertisement

Advertisement

Advertisement

© Copyright NDTV Convergence Limited 2015. All rights reserved.